Loading search results
ÉPIDERMAPS
Impact of Covid-19 on Occupational Dermato-allergology Consultations of Health Peronnel
Sponsor study identifier
observational
341
1 country
2
Study Start
March 15, 2024
Actual (reported)Primary Completion
February 9, 2025
Actual (reported)Study Completion
February 9, 2025
Actual (reported)Occupational dermatitis is the second most common occupational disease in Europe, with a notable prevalence among healthcare workers-approximately 20% of whom are affected. However, these figures may be underestimated due to underreporting. Despite the presumed scale of the problem, there is no recent European data providing real numbers. This study seeks to address the knowledge gap regarding the impact of the COVID-19 pandemic on occupational dermatitis within the healthcare workers population. EPIDERMAPS is a retrospective cohort study that analyzes data from two specialized centers in the Paris region. The primary goal is to assess changes in the proportion of dermatology-allergology consultations among healthcare workers before and after the COVID-19 pandemic. Secondary objectives include evaluating the pandemic's effect on occupational dermatoses incidences, attributed to increased PPE and hygiene products usage. The major focus will be on work-related allergic contact dermatitis, irritant contact dermatitis, contact urticaria, acne, and rosacea. The latter objective is to identify new allergens or contributing factors. Participants include active healthcare workers aged 18 or older who sought consultations for dermatological or dermatology-allergology related motifs between March 15, 2017, and March 15, 2023. Exclusions apply for patients who have consulted for other than dermatology-allergology related motif and those opposing to participate. Data will be stored, anonymized, and analyzed using EasyMedStat. Data collection is scheduled between March and December 2024. This research aims to offer insights into COVID-19's dermatologic and allergic effects on healthcare professionals, informing future preventive measures and enhanced care strategies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 9, 2025
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 31, 2024
Actual (reported)February 1, 2024
Actual (reported)March 15, 2024
Actual (reported)February 9, 2025
Actual (reported)February 9, 2025
Actual (reported)Proportion of occupational dermato-allergology consultations
Proportion of occupational dermato-allergology consultations
Day 1
Patients who consulted for the first time between 15th march 2017 and 15th march 2023 for an occupational dermato-allergological problem and occupying a health personnel position.
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000, France
Hôpital Hôtel Dieu
Paris, 75004, France
341 participants (actual enrollment reported by the registry).
First Submitted
January 31, 2024
First Posted
February 1, 2024
Study Start
March 15, 2024
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
February 9, 2025
Actual (reported)Study Completion
February 9, 2025
Actual (reported)Last Updated
December 15, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: